Androgen Receptor Signaling Inhibitors in Non-Metastatic Castration-Resistant Prostate Cancer in Japan: The ARASHI Study.

ABSTRACT:

Objectives

To describe clinical use and outcomes of androgen receptor signaling inhibitors (ARSIs) darolutamide, enzalutamide, and apalutamide in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) in Japan.

Methods

This retrospective, observational study examined health claims data from acute care hospitals (Medical Data Vision Co. Ltd. database) in Japan, for patients with nmCRPC initiating an ARSI between February 2020 and April 2023. Key outcomes were time to initial ARSI discontinuation and time to progression to metastatic castration-resistant prostate cancer (mCRPC).

Results

Of 2746 eligible patients, 418 (15%) received darolutamide, 1898 (69%) enzalutamide, and 430 (16%) apalutamide. Median follow-up was 18.1 months for darolutamide, 20.

SUBMITTER: Suzuki K 

PROVIDER: S-EPMC12687924 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature